Please assess the completion status of the following clinical trial:

Trial Title: Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Early (less than 2 years) HAM~* Progressing (within past 3 months) HAM~* Important to study the effect of therapy on disease that is most active as most likely to detect and measure improvement~Exclusion Criteria:~* HIV infection~* Tuberculosis, strongyloidiasis or other infection related to immune compromise~* Hepatitis B \& C viral infections~* Malignancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ciclosporin (Type: EXPERIMENTAL): 48 weeks treatment with ciclosporin

Based on this trial design, predict the completion outcome and termination type (if applicable).